Target axis mutant! Lilly's $1.35 billion acquisition of Disarm Therapeutics results in a new, powerful SARM1 inhibitor program!

October 16, 2020 // -- Eli Lilly recently announced a final agreement to acquire Disalm Therapeutics, a privately held biotech company dedicated to creating a new class of disease-correcting therapies for patients with axonal degeneration.
Disarm has discovered a new, powerful SARM1 inhibitor and is advancing it to preclinical research with the aim of providing breakthrough treatments for patients with peripheral neuropathy and other neurological disorders such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MM).
is a common but unresolved pathology that exists in a wide range of neurological diseases and is known to cause severe sensations, movement, and cognitive symptoms.
Jeffrey Milbrandt and Aaron DiAntonio of the University of Washington School of Medicine, founder of Disarm, found that the SARM1 protein is the central driver of axis mutations.
THERM1 inhibitors found by Disarm can be used to directly prevent shaft loss.
acquisition will expand Lilly's research and development efforts in pain and neurodegenerative changes, acquiring Disarm's promising preclinical preclinical SARM1 program for the treatment axis mutation.
under the terms of the agreement, Lilly will buy Disarm with an advance payment of $135 million.
if Lilly succeeds in developing and commercializing new drugs from the acquisition, Disarm shareholders will be eligible for development, regulatory and commercial milestone payments of up to $1,225 million.
Mark Mintun, Lilly's vice president of pain and neurodegenerative change studies, said,
Resociation continues to seek medications for degenerative pain and loss of function associated with nerve damage."
team at Disarm has found an important and promising way to combat axis mutations.
we will rapidly develop its SARM1 inhibitors as potential drugs for the treatment of peripheral neuropathy and neurological disorders such as ALS and MM.
": Lilly Announces Agreement to Acquire Disarm Therapeutics